CYTK

CK-274

Hypertrophic Cardiomyopathies (HCM)

Phase 2

Exp Date

End of 2020

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: CK-274 for Hypertrophic Cardiomyopathies (HCM) - Phase 2

  • ClinicalTrials.gov (NCT04219826): REDWOOD-HCM: Randomized Evaluation of Dosing With CK-3773274 in Obstructive Outflow Disease in HCM (REDWOOD-HCM)


WHAT IS THE NEXT CATALYST EVENT?

  • Summary Data From First Cohort Will Inform Progression To The Second Cohort Of The Trial, Expected By The End Of 2020.


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • End of 2020


PRIOR DATA

PRESS RELEASES

MECHANISM OF ACTION

  • CK-274 reduces the number of active actin-myosin cross bridges during each cardiac cycle and consequently reduces myocardial contractility.

Updated by JM 

CYTK, Cytokinetics, Hypertrophic Cardiomyopathies (HCM), CK-274

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon